Close Menu

NEW YORK – Fox Chase Cancer Center and digital health startup Genome Profiling (GenPro) have partnered to identify a new immune system epigenetic biomarker to predict patient response to anti-PD1 antibody checkpoint inhibitor therapy.

Wayne, Pennsylvania-based GenPro will use its EpiMarker machine-learning platform and method to identify an interactive network of genomic DNA methylation sites in patients' circulating immune cells that may be predictive of response to therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.